Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MUSIC-HFpEF: SRD-001 in HFpEF
NCT06061549Phase 1Recruiting
- Sponsor
- Sardocor
- Start
- Aug 2023
- Primary completion
- Aug 2025
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SRD-001 in heart failure with preserved ejection fraction (HFpEF), sponsored by Sardocor. Primary endpoint: Pulmonary Capillary Wedge Pressure at 52 weeks. Started Aug 2023; status: recruiting.
02
Drugs
SRD-001
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT06061549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06061549.